Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Topotecan lactone selectively binds to double- and single-stranded DNA in the absence of topoisomerase I.

Yao S, Murali D, Seetharamulu P, Haridas K, Petluru PN, Reddy DG, Hausheer FH.

Cancer Res. 1998 Sep 1;58(17):3782-6.

3.

Interaction of clinically important human DNA topoisomerase I poison, topotecan, with double-stranded DNA.

Streltsov S, Oleinikov V, Ermishov M, Mochalov K, Sukhanova A, Nechipurenko Y, Grokhovsky S, Zhuze A, Pluot M, Nabiev I.

Biopolymers. 2003;72(6):442-54.

PMID:
14587067
4.

[Interaction of topotecan, DNA topoisomerase I inhibitor, with double-stranded polydeoxyribonucleotides. 4. Topotecan binds preferably to the GC base pairs of DNA].

Strel'tsov SA, Mikheĭkin AL, Grokhovskiĭ SL, Oleĭnikov VA, Kudelina IA, Zhuze AL.

Mol Biol (Mosk). 2002 Sep-Oct;36(5):912-30. Russian.

PMID:
12391856
6.

Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH.

Gabr A, Kuin A, Aalders M, El-Gawly H, Smets LA.

Cancer Res. 1997 Nov 1;57(21):4811-6.

7.

[Interaction of topotecan, DNA topoisomerase I inhibitor, with double-stranded polydeoxyribonucleotides. III. Binding at the minor groove].

Strel'tsov SA, Mikheĭkin AL, Grokhovskiĭ SL, Oleĭnikov VA, Zhuze AL.

Mol Biol (Mosk). 2002 May-Jun;36(3):511-24. Russian.

PMID:
12068638
8.

Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.

Bailly C, Lansiaux A, Dassonneville L, Demarquay D, Coulomb H, Huchet M, Lavergne O, Bigg DC.

Biochemistry. 1999 Nov 23;38(47):15556-63.

PMID:
10569939
9.
10.

Multiple binding modes of the camptothecin family to DNA oligomers.

Bocian W, Kawecki R, Bednarek E, Sitkowski J, Pietrzyk A, Williamson MP, Hansen PE, Kozerski L.

Chemistry. 2004 Nov 5;10(22):5776-87.

PMID:
15472946
11.

Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties.

Lesueur-Ginot L, Demarquay D, Kiss R, Kasprzyk PG, Dassonneville L, Bailly C, Camara J, Lavergne O, Bigg DC.

Cancer Res. 1999 Jun 15;59(12):2939-43.

12.

Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.

Hofland K, Petersen BO, Falck J, Helin K, Jensen PB, Sehested M.

Clin Cancer Res. 2000 Apr;6(4):1488-97.

13.

Antitumor activity of XR5944, a novel and potent topoisomerase poison.

Stewart AJ, Mistry P, Dangerfield W, Bootle D, Baker M, Kofler B, Okiji S, Baguley BC, Denny WA, Charlton PA.

Anticancer Drugs. 2001 Apr;12(4):359-67.

PMID:
11335793
14.

NB-506, an indolocarbazole topoisomerase I inhibitor, binds preferentially to triplex DNA.

Ren J, Bailly C, Chaires JB.

FEBS Lett. 2000 Mar 31;470(3):355-9.

15.

Comparative brain tissue distribution of camptothecin and topotecan in the rat.

El-Gizawy SA, Hedaya MA.

Cancer Chemother Pharmacol. 1999;43(5):364-70.

PMID:
10100590
16.

Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.

Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C.

Oncology. 1999;56(1):1-12. Review.

PMID:
9885371
17.

[Interaction of topotecan--a DNA topoisomerase inhibitor--with dual-stranded polydeoxyribonucleotides. I. Dimerization of topotecan in solution].

Strel'tsov SA, Grokhovskiĭ SL, Kudelina IA, Oleĭnikov VA, Zhuze AL.

Mol Biol (Mosk). 2001 May-Jun;35(3):432-41. Russian.

PMID:
11443925
18.

Topotecan is a substrate for multidrug resistance associated protein 4.

Tian Q, Zhang J, Chan SY, Tan TM, Duan W, Huang M, Zhu YZ, Chan E, Yu Q, Nie YQ, Ho PC, Li Q, Ng KY, Yang HY, Wei H, Bian JS, Zhou SF.

Curr Drug Metab. 2006 Jan;7(1):105-18.

PMID:
16454695
19.

Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.

Sukhanova A, Grokhovsky S, Zhuze A, Devy J, Pluot M, Oleinikov V, Nabiev I.

Anticancer Res. 2003 May-Jun;23(3B):2609-15.

PMID:
12894548
20.

Supplemental Content

Support Center